ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Noninvasive Urinary Sediment Double Immunostaining Test Predicts BK Polyomavirus Nephropathy in Kidney Transplant Recipients

G. Huang1, X. Chen1, S. Yang1, X. Hou2, H. Yang3, C. Wang1

1The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 2Guangzhou KingMed Center for Clinical Laboratory Co, Ltd, Guangzhou, China, 3Fuda Cancer Hospital, Jinan University, Fuda Cancer Hospital, Guangzhou, China

Meeting: 2020 American Transplant Congress

Abstract number: A-218

Keywords: Biopsy, Kidney transplantation, Polyma virus, Urinalysis

Session Information

Session Name: Poster Session A: Kidney: Polyoma

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: This study aimed to improve the diagnostic value of decoy cells for BK polyomavirus associated-nephropathy (BKPyVAN) in kidney transplant recipients.

*Methods: A total of 105 urine sediment samples with decoy cells morphology (Figure 1) and BK DNA viruria were evaluated by double-immunostaining with anti-SV40T and anti-HGD (a renal tubular marker) or anti-S100P (a urothelial marker) (Figure 2).

*Results: Of all patients, 76 patients (70 with BKPyVAN) had HGD(+)/SV40 T(+) cells and S100P(+)/SV40 T(+) cells simultaneously (Figure 3), 24 patients (3 with BKPyVAN) had S100P(+)/SV40 T(+) cells only, and 5 patients (no BKPyVAN) had S100P(-)/HGD(-)/SV40 T(+) cells only. The sensitivity and specificity of decoy cells for BKPyVAN were 45.8%, and 68.8% respectively. The sensitivity and specificity of BKPyV viremia for BKPyVAN were 61.1%, and 84.2% respectively. By contrast, the sensitivity and specificity of HGD(+)/SV40 T(+) cells for BKPyVAN were 95.9%, and 81.3% respectively.

*Conclusions: Double-immunostaining with anti-S100P/SV40T and HGD/SV40T help identify the origin of decoy cells and predict BKPyVAN.

 border=

 border=

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Huang G, Chen X, Yang S, Hou X, Yang H, Wang C. The Noninvasive Urinary Sediment Double Immunostaining Test Predicts BK Polyomavirus Nephropathy in Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/the-noninvasive-urinary-sediment-double-immunostaining-test-predicts-bk-polyomavirus-nephropathy-in-kidney-transplant-recipients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences